Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2025)

Bioventus (BVS) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$650000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Asset Writedowns and Impairment fell 248.06% year-over-year to -$650000.0, compared with a TTM value of -$34.3 million through Sep 2025, up 25.06%, and an annual FY2024 reading of -$434000.0, up 60.65% over the prior year.
  • Asset Writedowns and Impairment was -$650000.0 for Q2 2025 at Bioventus, down from $650000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $34.4 million in Q3 2024 and bottomed at -$79.7 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 5 years is -$4.2 million, with a median of $330000.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 6157.6% in 2023, then skyrocketed 2679.63% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $623000.0 in 2021, then soared by 111.24% to $1.3 million in 2022, then crashed by 6157.6% to -$79.7 million in 2023, then soared by 56.93% to -$34.3 million in 2024, then soared by 98.11% to -$650000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for BVS at -$650000.0 in Q2 2025, $650000.0 in Q1 2025, and -$34.3 million in Q4 2024.